Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024
Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024
CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its first quarter 2024 financial results and provide an update on its business and pipeline on Wednesday, May 15, after the market close. The Company does not intend to host a conference call, and anticipates resuming quarterly earnings calls at the time it announces second quarter 2024 results.
馬薩諸塞州劍橋，2024年5月8日（GLOBE NEWSWIRE）——專注於識別和開發罕見病和耐多藥（MDR）細菌感染的新療法的多資產臨床階段生物製藥公司Spero Therapeutics, Inc.（納斯達克股票代碼：SPRO）今天宣佈，將在5月15日星期三公佈其2024年第一季度財務業績，並提供其業務和產品線的最新情況市場關閉。該公司不打算舉辦電話會議，並預計將在公佈2024年第二季度業績時恢復季度業績電話會議。
About Spero Therapeutics
關於斯佩羅療法
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections.
Spero Therapeutics總部位於馬薩諸塞州劍橋，是一家多資產、處於臨床階段的生物製藥公司，專注於識別和開發針對罕見疾病和耐多藥（MDR）細菌感染的新療法。
- Spero Therapeutics is developing its wholly owned lead product candidate, SPR720 as a novel oral, first-line treatment for nontuberculous mycobacterial pulmonary disease (NTM-PD), currently advancing in a Phase 2A proof of concept study. NTM-PD is a rare pulmonary disease caused by non-tuberculous mycobacterial infections.
- Spero Therapeutics正在開發其全資主要候選產品 SPR720，這是一種治療非結核分枝桿菌肺病（NTM-PD）的新型口服一線療法，目前正在進行2A期概念驗證研究。NTM-PD 是一種罕見的肺部疾病，由非結核分枝桿菌感染引起。
- Tebipenem HBr is an investigational oral drug advancing in a Phase 3 registrational trial for the treatment of complicated urinary tract infection (cUTI), including pyelonephritis. Spero granted GSK an exclusive license to commercialize tebipenem HBr in all territories, except certain Asian territories.
- Tebipenem HBr是一種正在研究的口服藥物，正在進行3期註冊試驗，用於治療包括腎盂腎炎在內的複雜尿路感染（CUTi）。Spero授予葛蘭素史克獨家許可，允許其在除某些亞洲地區以外的所有地區將替比培南HBr商業化。
- SPR206 is an innovative, investigational IV-administered direct-acting next generation polymyxin that has shown antibiotic activity against MDR Gram-negative pathogens, including carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in preclinical studies. An Investigational New Drug (IND) application has been cleared by the FDA to advance SPR206 into a Phase 2 clinical trial in participants with hospital-acquired or ventilator-associated bacterial pneumonia.
- SPR206 是一種創新的、正在研究的靜脈注射直接作用的下一代多粘菌素，在臨床前研究中已顯示出對耐多藥革蘭氏陰性病原體的抗生素活性，包括耐碳青黴烯類腸桿菌、鮑曼不動桿菌和銅綠假單胞菌。一項研究性新藥 (IND) 申請已獲得 FDA 批准，旨在將 SPR206 推進爲針對醫院獲得性或呼吸機相關細菌性肺炎參與者的二期臨床試驗。
For more information, visit .
欲了解更多信息，請訪問 。
Investor Relations Contact:
Ashley R. Robinson
Managing Director, LifeSci Advisors, LLC
arr@lifesciadvisors.com
(617) 775-5956
投資者關係聯繫人：
阿什莉·羅賓遜
LifeSCI Advisors, LLC董事總經理
arr@lifesciadvisors.com
(617) 775-5956
Media Inquiries: media@sperotherapeutics.com
媒體查詢：media@sperotherapeutics.com
譯文內容由第三人軟體翻譯。